Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: A total of 121 patients received PLD and 120 patients the BV combination. The response to PLD was superior to BV: 58.7% versus 23.3% (P < .001). Patients who were randomized to receive BV, however, were more likely to terminate treatment early because of an adverse event (26.7% v 10.7%), and fewer completed the full six cycles of treatment (30.8% v 55.4%). Treatment with BV was associated with a significantly higher incidence of peripheral neuropathy (P < .001), whereas PLD treatment was more commonly associated with neutropenia and delays in receiving treatment (P < or = .001). CONCLUSION:
|
Authors | S Stewart, H Jablonowski, F D Goebel, K Arasteh, M Spittle, A Rios, D Aboulafia, J Galleshaw, B J Dezube |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 16
Issue 2
Pg. 683-91
(Feb 1998)
ISSN: 0732-183X [Print] United States |
PMID | 9469358
(Publication Type: Clinical Trial, Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Drug Carriers
- Liposomes
- Bleomycin
- Vincristine
- Doxorubicin
|
Topics |
- Acquired Immunodeficiency Syndrome
(complications)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bleomycin
(administration & dosage, adverse effects)
- Doxorubicin
(adverse effects, therapeutic use)
- Drug Carriers
- Humans
- Liposomes
- Prospective Studies
- Sarcoma, Kaposi
(complications, drug therapy)
- Vincristine
(administration & dosage, adverse effects)
|